Holen Sie sich die Stockscreener-App
82.24
3.10%
-2.63
Handel nachbörslich:
82.14
-0.10
-0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$84.87
Offen:
$83.39
24-Stunden-Volumen:
1.89M
Relative Volume:
0.75
Marktkapitalisierung:
$11.17B
Einnahmen:
$105.82M
Nettoeinkommen (Verlust:
$-829.61M
KGV:
-12.02
EPS:
-6.8429
Netto-Cashflow:
$-548.92M
1W Leistung:
-3.89%
1M Leistung:
+17.23%
6M Leistung:
+29.86%
1J Leistung:
+122.21%
1-Tages-Spanne:
$80.90
$84.60
1-Wochen-Bereich:
$80.90
$87.93
52-Wochen-Spanne:
$32.89
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
82.24 | 11.52B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Wells Fargo | Overweight |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-18 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Is Cytokinetics (CYTK) A Bargain On Myqorzo Approval Or Already Fully Priced? - Yahoo Finance
How Myqorzo’s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story - Yahoo Finance
Price to sales forward of Cytokinetics, Incorporated – NASDAQ:CYTK - TradingView
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure? - Yahoo Finance
Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $108.47, Implies 26% Upside - TradingView
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
FMR LLC holds 5.25M shares of Cytokinetics (NASDAQ: CYTK) in 13G/A - Stock Titan
CYTOKINETICS (CYTK) EVP exercises options, sells 3,500 shares in open market - Stock Titan
CYTK (NASDAQ: CYTK) files Form 144 for 24,500-share option exercise sale - Stock Titan
Cytokinetics’ SWOT analysis: cardiovascular stock eyes growth with Myqorzo By Investing.com - Investing.com Nigeria
Cytokinetics’ SWOT analysis: cardiovascular stock eyes growth with Myqorzo - Investing.com
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Cuts Target Price to $117 - Moomoo
CYTK Maintained by RBC Capital -- Price Target Lowered to $117 - GuruFocus
RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating - marketscreener.com
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 - The Manila Times
Cytokinetics lands three ESC 2026 presentations on heart drug data - Stock Titan
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of ... - Caledonian Record
CYTKCytokinetics Inc Latest SEC Filings - Finviz
Cytokinetics CEO Robert Blum sells $636,900 in stock - Investing.com UK
Insider Sell Alert: EVP, Chief Financial Officer Sung Lee Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
CYTK News | CYTOKINETICS INC (NASDAQ:CYTK) - ChartMill
Cytokinetics EVP Andrew Callos sells $1.29 million in shares - Investing.com UK
Cytokinetics CEO Robert Blum sells $636,900 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $1.29 million in shares By Investing.com - Investing.com South Africa
Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (NASDAQ: CYTK) CEO trims stake with 7,500-share sale - Stock Titan
Cytokinetics (NASDAQ: CYTK) EVP exercises options, sells 15,000 shares at $85.80 - Stock Titan
CYTOKINETICS (NASDAQ: CYTK) CFO exercises options, sells 1,112 shares at $87.79 - Stock Titan
Form 144 CYTOKINETICS For: 1 July By Investing.com - Investing.com UK
CYTK insider Robert Blum notifies planned sale of 44,990 shares (CYTK) - Stock Titan
Cytokinetics Inc stock hits 52-week high at $88.00 - Investing.com
Cytokinetics Inc stock hits 52-week high at $88.00 By Investing.com - Investing.com India
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Cytokinetics (CYTK) - The Globe and Mail
Cytokinetics CFO Lee Sung sells $3.18m in company stock By Investing.com - Investing.com South Africa
Cytokinetics CFO Lee Sung sells $3.18m in company stock - Investing.com
Form 144 CYTOKINETICS For: 29 June By Investing.com - Investing.com South Africa
Form 4 Cytokinetics Inc For: 29 June By Investing.com - Investing.com South Africa
Cytokinetics(CYTK.US) Officer Sells US$3.19 Million in Common Stock - Moomoo
Cytokinetics (CYTK) CFO sells 38,730 shares at $82.30 after exercising options - Stock Titan
Cytokinetics CFO Lee Sung sells $266,390 of company stock By Investing.com - Investing.com South Africa
Cytokinetics CFO Lee Sung sells $266,390 of company stock - Investing.com
Cytokinetics (NASDAQ: CYTK) CFO trades shares after option exercises - Stock Titan
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytokinetics Inc-Aktie (CYTK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Jul 07 '26 |
Sale |
86.62 |
3,500 |
303,170 |
153,902 |
5.60%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):